Why Are My Ct Values Above 35 — and Should I Be Worried?

A Ct above 35 usually means one of three things: your target is genuinely present at very low abundance, you have primer-dimer or off-target amplification creeping in, or something went wrong upstream (bad RNA, failed RT, wrong primer pair). The answer to "should I be worried" depends entirely on which of those three you're dealing with — and you can usually figure it out in about ten minutes with your melt curve data and a few controls.

The short version: a Ct of 35-38 can be real, especially for low-abundance transcripts like cytokines in unstimulated cells, rare splice variants, or viral targets near the limit of detection. But you need to demonstrate it's real — a single late Ct with no melt curve analysis and no NTC context is not publishable data, and honestly shouldn't even make it into your lab notebook as a confident measurement. Here's how to triage.

Check Your NTCs First

Your no-template controls are the first thing to look at when you see late Ct values. If your NTCs are coming up at Ct 37-40, and your samples are at Ct 35-36, you do not have a meaningful signal-to-noise gap. You're essentially measuring the same thing as your negative control.

For SYBR Green / intercalating dye chemistries (PowerUp SYBR, Luna Universal, etc.), NTC amplification at Ct 37+ is extremely common and almost always primer-dimer. This is normal behavior — it doesn't mean your primers are "bad," it means two oligonucleotides at 200-400 nM in a tube with a polymerase will eventually find each other. The critical question is how far your sample Ct sits from your NTC Ct:

• Sample Ct at least 5 cycles below NTC Ct: Your signal is ~32-fold above background. Generally trustworthy if the melt curve checks out.
• Sample Ct 3-5 cycles below NTC Ct: Gray zone. You might have real signal contaminated with some primer-dimer contribution. Proceed with caution, increase replicates, and lean on melt curves hard.
• Sample Ct within 2 cycles of NTC Ct: This is not signal. This is noise. Report it as undetected or below the limit of quantification.

For TaqMan assays, NTCs should genuinely stay flat — no amplification at all. If you're seeing NTC amplification with probe-based chemistry, you likely have contamination (template carryover, plasmid dust from a colleague's cloning project) rather than primer-dimer, and that's a different problem.

What the Melt Curve Tells You

If you're running SYBR-based detection and you're not checking melt curves for late-Ct samples, you're flying blind. Open your melt curve data — on a CFX96 or QuantStudio, this is trivially easy — and look for two things:

Single peak at the expected Tm? Good. If your target amplicon melts at 82°C and your late-Ct samples show a clean, single peak at 82°C, that's strong evidence of specific amplification. The signal is real, just low.

Broad peak, shoulder, or second peak at a lower Tm (often 72-78°C)? That lower-Tm peak is almost certainly primer-dimer. If it's the only peak in your late-Ct wells, the entire Ct value is driven by non-specific product. If it's a shoulder alongside your real peak, your Ct is a composite of real signal and artifact, which means it's quantitatively unreliable even if your target is technically present.

One practical move: if you see mixed melt curves, run 5 µL of the qPCR product on a 2% agarose gel (or even better, a 4% gel if your amplicon is short). You'll immediately see whether you have a band at the expected size, a fuzzy blob at 40-60 bp (primer-dimer), or both.

Common Reasons for Legitimately Late Ct Values

Not every Ct above 35 is a problem. Some targets are just scarce, and your assay might be performing exactly as expected:

Low-abundance transcripts. Genes like IL-2 in resting T cells, CYP1A1 in untreated hepatocytes, or most transcription factors in bulk tissue can easily sit at Ct 33-37. If your reference gene (GAPDH, ACTB) is at Ct 15-18 in the same samples, a ΔCt of 18-20 is biologically consistent with a transcript present at a few copies per cell.

Low input. If you're working with laser-capture microdissected tissue, sorted rare cell populations, or liquid biopsy samples, you might have started with 1-10 ng of total RNA. Even abundant transcripts can push to Ct 30+, and your targets of interest will follow accordingly. The key metric here is whether your reference genes shifted proportionally — if GAPDH went from Ct 16 to Ct 28 because of low input, your GOI going from Ct 28 to Ct 38 is the same ΔCt and may be perfectly valid.

FFPE-derived RNA. Formalin-fixed samples yield fragmented RNA, and longer amplicons will suffer more than short ones. If your primers span 150+ bp, consider redesigning to 70-90 bp amplicons. This alone can rescue 2-4 Ct values worth of signal from degraded templates.

Viral detection near the limit. In clinical or environmental virology, a Ct of 36-38 for SARS-CoV-2 or influenza might represent genuine low-level virus. Most clinical labs have established cutoffs (often Ct 40 with probe-based assays on validated platforms) and report these as "detected" with appropriate caveats. The context is everything.

Common Reasons for Artifactually Late Ct Values

If your targets should not be this scarce — if GAPDH itself is coming up at Ct 30+ from a standard cell pellet extraction — something is wrong upstream:

Poor RNA quality. Check your RIN/RQN if you have a Bioanalyzer or TapeStation trace. A RIN below 5 means significant degradation, and your cDNA synthesis probably yielded incomplete transcripts. Even a 260/280 ratio on the NanoDrop only tells you about protein contamination, not integrity.

Failed or inefficient reverse transcription. Old RT enzyme, degraded random hexamers, too much RNA input saturating the reaction, or residual genomic DNA competing for primers. If you're using oligo(dT) priming exclusively, transcripts with long 3' UTRs or secondary structure can under-represent. Consider switching to random hexamers or a blend.

Genomic DNA contamination (without DNase treatment). If your primers don't span an intron — or your gene is an intronless retroprocessed pseudogene (looking at you, GAPDH and ACTB) — you might be amplifying gDNA at late cycles. A no-RT control (NRT) is non-negotiable here. If your NRT gives a Ct within 5 cycles of your sample, your data is compromised.

Inhibitors carried over from extraction. Phenol, ethanol, guanidinium salts, heparin (from blood samples), humic acid (from soil/environmental samples) — all of these can reduce polymerase efficiency and push Ct values later. A simple test: spike a known positive control into your sample matrix. If the Ct shifts later compared to the spike in clean water, you have inhibition.

How to Set a Defensible Ct Cutoff

There's no universal "Ct cutoff" that applies to all assays. The commonly cited "Ct 35" threshold is a rough heuristic, not a physical law. Here's a more principled way to set yours:

1. Run a standard curve with serial dilutions of your template (cDNA, plasmid, gDNA — whatever's appropriate) from high concentration down to sub-single-copy if feasible. Use at least 5 points, 10-fold dilutions, in triplicate.

2. Find where replicates start to diverge. At high template concentrations, your triplicate Ct SD should be <0.2. As you go lower, the SD will increase. When your replicate CV exceeds 0.5-1.0 Ct, you're at the stochastic zone — Poisson sampling noise is dominating because some wells got 1 copy and some got 0.

3. That divergence point is your assay's limit of quantification (LOQ). Below it, you can call presence/absence but not quantify reliably. Report it in your methods: "The LOQ for the IL-6 assay was determined to be Ct 36.5 based on replicate reproducibility in standard curve analysis."

4. Your limit of detection (LOD) is the last dilution where at least some replicates (often defined as ≥95%) show amplification with the correct melt curve or probe signal. This is often 1-3 cycles beyond the LOQ.

For most well-designed assays with 90-110% efficiency and amplicons of 80-150 bp, the LOQ tends to land around Ct 34-37 and the LOD around Ct 37-39. But your assay is your assay — measure it, don't assume it.

What to Do With Late Ct Data Points

If you've confirmed the signal is real (melt curve clean, well separated from NTC, replicates reasonably tight), you can use the data — but be transparent:

• For relative quantification (ΔΔCt): Late Ct values propagate larger fold-change errors. A ΔCt of 15 ± 0.5 represents a bigger window of uncertainty on the fold-change scale than a ΔCt of 5 ± 0.5. Consider reporting the ΔCt values with confidence intervals rather than just the fold-change bar graph.

• For absolute quantification: Make sure your standard curve actually extends into the Ct range of your unknowns. Extrapolating beyond your lowest standard is a recipe for inaccurate copy numbers.

• For presence/absence calls: Late Ct values are fine for qualitative detection, provided you've established your LOD. "Detected at Ct 37.2 (assay LOD = Ct 38.5)" is a valid statement.

• For statistics: Run your tests on ΔCt values, not fold changes. Fold changes are on a log scale and violate normality assumptions for parametric tests. If you're comparing groups where some samples are "undetected," you need to make a decision: assign them a Ct at the assay LOD, exclude them, or use a non-parametric approach. There's no perfect answer, but you should state what you did.

If you're spending too much time manually checking melt curves, flagging NTC bleed-through, and triaging late-Ct wells, VoilaPCR handles this automatically — it flags wells with Ct values near NTC, checks melt curve consistency, and marks samples below your assay's quantification limit so you can focus on interpreting biology instead of auditing raw data.